A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor

Parkinsonism and Related Disorders

Volumn 9, Issue 6, 2003, Pages 341-347

  Lee, Kwang Soo ^a   Kim, Joong Seok ^a   Kim, Jae Woo ^b   Lee, Won Yong ^c   Jeon, Beum Seok ^d   Kim, Dongjae ^e  

^a The Catholic University of Korea   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e The Catholic University of Korea   (South Korea)

Author keywords

Arotinolol; Essential tremor; Propranolol

Indexed keywords

AROTINOLOL; PROPRANOLOL;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISABILITY; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; ESSENTIAL TREMOR; EVALUATION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; RASH; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; STOMACH DISEASE; TREATMENT OUTCOME; VERTIGO;

EID: 0038692174     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(03)00029-4     Document Type: Article

References (31)

1. Lou J.S., Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology. 41:1991;234-238.
2. Louis E.D., Ottman R., Houser W.A. How common is the most common adult movement disorder? Estimates of prevalence of essential tremor throughout the world. Mov Disord. 13:1998;5-10.
3. Findley L.J., Koller W.C. Essential tremor: a review. Neurology. 37:1987;1194-1197.
4. Koller W., Biary N., Cone S. Disability in essential tremor: effect of treatment. Neurology. 36:1986;1001-1004.
5. Busenbark K.L., Nash J., Nash S., Hubble J.P., Koller W.C. Is essential tremor benign? Neurology. 41:1991;1982-1983.
6. Hubble J.P., Busenbark K.L., Koller W.C. Essential tremor. Clin Neuropharmacol. 12:1989;453-482.
7. Koller W.C., Hristova A., Brin M. Pharmacologic treatment of essential tremor. Neurology. 54:2000;S30-S38.
8. Winkler G.F., Young R.R. Efficacy of chronic propranolol therapy in action tremors of the familial, senile or essential varieties. N Engl J Med. 290:1974;984-988.
9. O'Brien M.D., Upton A.R., Toseland P.A. Benign familial tremor treated with primidone. BMJ. 282:1981;178-180.
10. Findley L.J., Cleeves L., Calzetti S. Primidone in essential tremor of the hands and head: double-blind controlled clinical study. J Neurol Neurosurg Psychiatry. 48:1985;911-915.
11. Calzetti S., Findley L.J., Perucca E., Richens A. The response of essential tremor to propranolol: evaluation of clinical variables governing its efficacy on prolonged administration. J Neurol Neurosurg Psychiatry. 46:1983;393-398.
12. Koller W.C., Royse V.L. Efficacy of primidone in essential tremor. Neurology. 36:1986;121-124.
13. Gorman W.P., Cooper R., Pocock P., Campbell M.J. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry. 49:1986;64-68.
14. Hara Y., Sato E., Miyagishi A., Aono S., Nakatani H. Pharmacological properties of DL-2-(3(-t-butylamino-2(-hydroxypropyl-thio)-4-(5(-carbomoyl-2(-thienyl) thiazole hydrochloride (S-596): new beta-adrenergic blocking agent. Folia Pharmacol Jap. 75:1979;707-720.
15. Iba K., Mizuno K., Kimura K., Miyawaki H. Profile of arotinolol. Imai S., Sogabe H., Ozaki M., Sakanashi M. Pharmacology of arotinolol. 1985;15-22 Sumitomo, Osaka.
16. Iba K., Mizuno K., Kimura K., Miyawaki H. Pharmacokinetic study of S-596 in mice and rats. Clin Report. 21:1987;4549-4579.
17. Kuroda Y., Kakigi R., Shibasaki H. Treatment of essential tremor with arotinolol. Neurology. 38:1988;650-652.
18. Takahashi A., Matsuoka Y., Yamamoto H., Mukai E., Indo T. Clinical efficacy of arotinolol for essential tremor: a phase 2 multicenter open trials. Rinsho Shinkechiryogaku. 10:1993;229-240.
19. Yanagisawa N., Tashiro K., Tohgi H., Mizuno Y., Tanabe H., Kowa H., Hirose G., Ebihara A. Clinical evaluation of arotinolol for essential tremor: a dose-finding multi-center double blind study. Risho Ninsyoigaku. 9:1993;1343-1371.
20. Jancovic J. Essential tremor: clinical characteristics. Neurology. 54:2000;S21-S25.
21. Fahn S., Tolosa E., Marin C. Clinical rating scale for tremor. Jancovic J., Tolosa E. Parkinson's disease and movement disorders. 1993;271-280 Williams and Wilkins, Baltimore, MD.
22. Stoudemire A., Brown J.T., Harris R.T., Blessing-Feussner C., Roberts J.H., Nichols J.C., Houpt J.L. Propranolol and depression: a reevaluation based on a pilot clinical trial. Psychiatr Med. 2:1984;211-218.
23. Cleeves L., Findley L.J. Propranolol and propranolol-LA in essential tremor: a double blind comparative study. J Neurol Neurosurg Psychiatry. 51:1988;379-384.
24. Weiss R.J. Effects of antihypertensive agents on sexual function. Am Fam Physician. 44:1991;2075-2082.
25. Hara Y., Natsume Y., Hara N. Suppressing effect of arotinolol, an α- and β-blocker, on oxotremorine-induced tremor in mice. Pharmacometrics. 41:1991;25-30.
26. Caccia M.R., Osio M., Galimberti V., Cataldi G., Mangoni A. Propranolol, clonidine, urapidil and trazodone infusion in essential tremor: a double-blind crossover trial. Acta Neurol Scand. 79:1989;379-383.
27. Mai J., Olsen R.B. Depression of essential tremor by alpha-adrenergic blockade. J Neurol Neurosurg Psychiatry. 44:1981;1171.
28. Owen D.A., Marsden C.D. Effect of adrenergic β-blockage on Parkinsonian tremor. Lancet. 2:1965;1259-1962.
29. Koller W.C. Dose-response relationship of propranolol in the treatment of essential tremor. Arch Neurol. 43:1986;42-43.
30. Tolosa E.S., Loewenson R.B. Essential tremor: treatment with propranolol. Neurology. 25:1975;1041-1044.
31. Takahashi A., Okamoto S., Yamamoto H., Indo T. Dose-response relationship of propranolol in the treatment of essential tremor and Parkinsonian Tremor. Rinsho Shinaichiryo. 6:1989;69-76.